Schonfeld Strategic Advisors LLC Invests $426,000 in SI-BONE, Inc. (NASDAQ:SIBN)

Schonfeld Strategic Advisors LLC purchased a new stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 30,400 shares of the company's stock, valued at approximately $426,000. Schonfeld Strategic Advisors LLC owned approximately 0.07% of SI-BONE as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. American Century Companies Inc. increased its position in shares of SI-BONE by 11.0% during the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares during the last quarter. Geode Capital Management LLC grew its position in SI-BONE by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock valued at $13,097,000 after acquiring an additional 9,847 shares during the last quarter. Impax Asset Management Group plc grew its position in SI-BONE by 1.1% during the fourth quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock valued at $10,750,000 after acquiring an additional 8,240 shares during the last quarter. Pier Capital LLC raised its stake in shares of SI-BONE by 1.6% during the fourth quarter. Pier Capital LLC now owns 473,123 shares of the company's stock worth $6,633,000 after acquiring an additional 7,225 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of SI-BONE by 6.3% in the 4th quarter. Northern Trust Corp now owns 409,122 shares of the company's stock worth $5,736,000 after acquiring an additional 24,214 shares during the last quarter. Institutional investors own 98.11% of the company's stock.

Insider Transactions at SI-BONE

In other SI-BONE news, CEO Laura Francis sold 38,504 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total value of $661,498.72. Following the completion of the transaction, the chief executive officer now directly owns 302,958 shares in the company, valued at approximately $5,204,818.44. This represents a 11.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,153 shares of company stock worth $935,040. 4.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on SIBN shares. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Truist Financial raised their price objective on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th.

SI-BONE Trading Up 2.0%

SIBN traded up $0.37 during trading on Friday, hitting $19.25. 233,117 shares of the stock traded hands, compared to its average volume of 371,274. The firm has a market capitalization of $820.34 million, a P/E ratio of -20.92 and a beta of 0.82. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $19.49. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a 50-day moving average of $14.74 and a 200 day moving average of $14.97.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities research analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current year.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.